Dernovsek M Z, Tavcar R
University Psychiatric Hospital, Ljubljana-Polje, Slovenia.
Int Clin Psychopharmacol. 2000 Jul;15(4):237-8. doi: 10.1097/00004850-200015040-00008.
We report a 2-year experience with olanzapine treatment (20 mg daily) in a 65-year-old male patient with treatment-resistant paranoid schizophrenia, who had previously developed leucopenia and neutropenia first on clozapine and, subsequently, also on risperidone. Olanzapine seems to be safe in this patient, since no major decreases of haematological parameters were observed. The only exception was a brief decrease of leucocyte and neutrophil (but not erythrocyte or platelet) counts during influenza-like viral infection. However, the control of psychotic symptoms on olanzapine is not as good as on clozapine.
我们报告了一名65岁男性难治性偏执型精神分裂症患者使用奥氮平（每日20毫克）治疗两年的经验。该患者先前使用氯氮平后出现白细胞减少和中性粒细胞减少，随后使用利培酮时也出现了同样情况。奥氮平在该患者中似乎是安全的，因为未观察到血液学参数的显著下降。唯一的例外是在类似流感的病毒感染期间白细胞和中性粒细胞（但红细胞或血小板未出现）计数短暂下降。然而，奥氮平对精神病症状的控制不如氯氮平。
